<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880473</url>
  </required_header>
  <id_info>
    <org_study_id>Entac-PrevisEA-001</org_study_id>
    <nct_id>NCT04880473</nct_id>
  </id_info>
  <brief_title>Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment</brief_title>
  <official_title>A Minimal-Risk, Multi-Center, Prospective, Clinical Trial to Evaluate the PrevisEA Device for Predicting Gastrointestinal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entac Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entac Medical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds&#xD;
      produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is&#xD;
      most commonly associated with postoperative ileus (POI), but could be the result of other&#xD;
      causes, such as early postoperative bowel obstruction. GII is defined as failure of&#xD;
      successful early oral re-feeding in a subject undergoing major abdominal surgery. For&#xD;
      subjects who are allowed to resume a diet during the first 24 hours after surgery, a failure&#xD;
      to successfully orally re-feed a subject is defined as presentation with emesis, requiring a&#xD;
      reversal of diet, or the placement of a nasogastric tube on first postoperative day or later.&#xD;
&#xD;
      The device is considered non-significant risk (NSR). The device does not inform medical&#xD;
      decisions in this study. Researchers will be blinded to results of the device during this&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of the PrevisEA device</measure>
    <time_frame>1-14 days</time_frame>
    <description>The performance (accuracy) of the device in predicting development of GII will be assessed through evaluation of the primary outcome measures of sensitivity and specificity for the device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV)</measure>
    <time_frame>1-14 days</time_frame>
    <description>Measures will be analyzed by using available data only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value (NPV)</measure>
    <time_frame>1-14 days</time_frame>
    <description>Measures will be analyzed by using available data only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall percent agreement (OPA)</measure>
    <time_frame>1-14 days</time_frame>
    <description>Measures will be analyzed by using available data only</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Gastrointestinal Complication</condition>
  <arm_group>
    <arm_group_label>PrevisEA device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PrevisEA device</intervention_name>
    <description>The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.</description>
    <arm_group_label>PrevisEA device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 90 years&#xD;
&#xD;
          2. Patient undergoing elective intestinal resection surgery including open, laparoscopic,&#xD;
             robotic, or hand-assist technique for:&#xD;
&#xD;
               1. Segmental ileocolic resection with or without diversion&#xD;
&#xD;
               2. Segmental colon resection with or without diversion&#xD;
&#xD;
               3. Segmental coloproctectomy with or without diversion&#xD;
&#xD;
               4. Low anterior resection with or without diversion&#xD;
&#xD;
               5. Abdominoperineal resection&#xD;
&#xD;
               6. Total abdominal colectomy with or without diversion&#xD;
&#xD;
               7. Proctocolectomy with or without end ileostomy or diversion&#xD;
&#xD;
               8. Closure of end colostomy (Hartmann's reversal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergies to any of the device components (i.e., adhesive)&#xD;
&#xD;
          2. Inability to have prototype device applied to their abdominal wall due to disease&#xD;
             conditions or surgical alterations(e.g., fistulas, stomas, drains, etc.)&#xD;
&#xD;
          3. Patients undergoing:&#xD;
&#xD;
               1. Small bowel resection without colonic resection&#xD;
&#xD;
               2. Transanal proctectomy without transabdominal approach&#xD;
&#xD;
               3. Perineal proctosigmoidectomy&#xD;
&#xD;
               4. Closure of loop colostomy or ileostomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Entac Medical Inc.</last_name>
    <phone>845-773-8473</phone>
    <email>previsea-001@clinicalresearchstrategies.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adventist Health System/Sunbelt, Inc. d/b/a AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Entac Medical Inc.</last_name>
      <email>previsea-001@clinicalresearchstrategies.com</email>
    </contact>
    <investigator>
      <last_name>John Monson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Albert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa deBeche-Adams, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesse Wright, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Soliman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Nassiff, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Entac Medical Inc.</last_name>
      <email>previsea-001@clinicalresearchstrategies.com</email>
    </contact>
    <investigator>
      <last_name>Vitaliy Y Poylin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health System</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Entac Medical Inc.</last_name>
      <email>previsea-001@clinicalresearchstrategies.com</email>
    </contact>
    <investigator>
      <last_name>Donald G Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Entac Medical Inc.</last_name>
      <email>previsea-001@clinicalresearchstrategies.com</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Gaertner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Madoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyrus Jahansouz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elliot Arsoniadis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Greeno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Genevieve Melton-Meaux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Entac Medical Inc.</last_name>
      <email>previsea-001@clinicalresearchstrategies.com</email>
    </contact>
    <investigator>
      <last_name>Kellie Mathis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-1350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Entac Medical Inc.</last_name>
      <email>previsea-001@clinicalresearchstrategies.com</email>
    </contact>
    <investigator>
      <last_name>Muneera R Kapadia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Guillem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Stem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Entac Medical Inc.</last_name>
      <email>previsea-001@clinicalresearchstrategies.com</email>
    </contact>
    <investigator>
      <last_name>Stefan D Holubar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott R Steele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative ileus</keyword>
  <keyword>Postoperative bowel obstruction</keyword>
  <keyword>Emesis</keyword>
  <keyword>Reversal of diet</keyword>
  <keyword>Nasogastric tube</keyword>
  <keyword>Abdominal sounds</keyword>
  <keyword>Gastrointestinal impairment</keyword>
  <keyword>Elective intestinal resection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

